We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
The Mosaic Company
MOS
$7.34B
| $11M | 0.02% |
223,468
-151,625
| -40% | -$7.47M |
|
|
COV
327
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $11M | 0.02% |
122,441
-72,210
| -37% | -$5.4M |
|
|
CELG
328
DELISTED
Celgene Corp
CELG
| $11M | 0.02% |
128,424
+1,008
| +0.8% | +$76.7K |
|
329
Invesco BuyBack Achievers ETF
PKW
$1.73B
| $11M | 0.02% |
245,040
-185,000
| -43% | -$8.1M |
|
|
LOCK
330
DELISTED
LifeLock, Inc.
LOCK
| $11M | 0.02% |
786,642
-127,707
| -14% | -$1.75M |
|
|
FL
331
DELISTED
Foot Locker
FL
| $10.8M | 0.02% |
212,100
-65,547
| -24% | -$3.13M |
|
332
Pinnacle West Capital
PNW
$12.8B
| $10.7M | 0.02% |
185,425
-15,650
| -8% | -$866K |
|
333
Intuit
INTU
$85.6B
| $10.5M | 0.02% |
130,994
+29,188
| +29% | +$2.25M |
|
|
VGR
334
DELISTED
Vector Group Ltd.
VGR
| $10.5M | 0.02% |
962,389
| – | – |
|
335
Alaska Air
ALK
$5.42B
| $10.5M | 0.02% |
221,124
-14,444
| -6% | -$688K |
|
336
NETSCOUT
NTCT
$2.89B
| $10.5M | 0.02% |
236,174
-434,469
| -65% | -$16.9M |
|
337
State Street
STT
$50.2B
| $10.5M | 0.02% |
155,660
-10,140
| -6% | -$667K |
|
338
WisdomTree Japan Hedged Equity Fund
DXJ
$7.12B
| $10.5M | 0.02% |
+211,795
| New | +$10M |
|
|
BEAV
339
DELISTED
B/E Aerospace Inc
BEAV
| $10.4M | 0.02% |
155,017
+18,207
| +13% | +$1.21M |
|
|
XLNX
340
DELISTED
Xilinx Inc
XLNX
| $10.4M | 0.02% |
219,206
-17,079
| -7% | -$822K |
|
|
BSFT
341
DELISTED
BroadSoft, Inc.
BSFT
| $10.2M | 0.02% |
385,235
+113,990
| +42% | +$2.73M |
|
342
Marathon Petroleum
MPC
$89.3B
| $10.1M | 0.02% |
259,316
-26,136
| -9% | -$1.16M |
|
343
Encore Capital Group
ECPG
$2.06B
| $10M | 0.02% |
220,872
+21,800
| +11% | +$964K |
|
344
Tyson Foods
TSN
$21.5B
| $10M | 0.02% |
266,752
+204
| +0.1% | +$8.17K |
|
345
Stewart Information Services
STC
$2.12B
| $10M | 0.02% |
322,798
| – | – |
|
346
Jones Lang LaSalle
JLL
$15.9B
| $9.75M | 0.02% |
77,130
-5,396
| -7% | -$650K |
|
347
Healthpeak Properties
DOC
$15.7B
| $9.74M | 0.02% |
258,429
-37,962
| -13% | -$1.43M |
|
348
MACOM Technology Solutions
MTSI
$19B
| $9.72M | 0.02% |
432,600
+116,891
| +37% | +$2.25M |
|
349
Conagra Brands
CAG
$7.38B
| $9.7M | 0.02% |
+419,810
| New | +$10.2M |
|
|
LGF
350
DELISTED
Lions Gate Entertainment
LGF
| $9.54M | 0.02% |
333,722
| – | – |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.